Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and PPARα knockout mouse hepatocytes

Melissa M Heintz,William D Klaren,Alexander W East,Laurie C Haws,Steven R McGreal,Rebecca R Campbell,Chad M Thompson

DOI: https://doi.org/10.1093/toxsci/kfae045

2024-04-04

Toxicological Sciences

Abstract:Abstract Recent in vitro transcriptomic analyses for the short-chain polyfluoroalkyl substance, HFPO-DA (ammonium, 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate), support conclusions from in vivo data that HFPO-DA-mediated liver effects in mice are part of the early key events of the peroxisome proliferator-activated receptor alpha (PPARα) activator-induced rodent hepatocarcinogenesis mode of action (MOA). Transcriptomic responses in HFPO-DA-treated rodent hepatocytes have high concordance with those treated with a PPARα agonist and lack concordance with those treated with PPARγ agonists or cytotoxic agents. To elucidate whether HFPO-DA-mediated transcriptomic responses in mouse liver are PPARα-dependent, additional transcriptomic analyses were conducted on samples from primary PPARα knockout (KO) and wild-type (WT) mouse hepatocytes exposed for 12, 24, or 72 h with various concentrations of HFPO-DA, or well-established agonists of PPARα (GW7647) and PPARγ (rosiglitazone), or cytotoxic agents (acetaminophen or d-galactosamine). Pathway and predicted upstream regulator-level responses were highly concordant between HFPO-DA and GW7647 in WT hepatocytes. A similar pattern was observed in PPARα KO hepatocytes, albeit with a distinct temporal and concentration-dependent delay potentially mediated by compensatory responses. This delay was not observed in PPARα KO hepatocytes exposed to rosiglitazone, acetaminophen, d-galactosamine. The similarity in transcriptomic signaling between HFPO-DA and GW7647 in both the presence and absence of PPARα in vitro indicates these compounds share a common MOA.

toxicology

What problem does this paper attempt to address?

The paper aims to investigate whether the transcriptomic response of short-chain perfluoroalkyl substance HFPO-DA in mouse hepatocytes is dependent on peroxisome proliferator-activated receptor alpha (PPARα). Specifically, the study compares the transcriptomic changes in wild-type (WT) and PPARα knockout (KO) mouse hepatocytes after treatment with HFPO-DA, PPARα agonist GW7647, PPARγ agonist rosiglitazone, and cytotoxic agents acetaminophen and N-acetyl-D-galactosamine to verify whether the liver effects induced by HFPO-DA are related to PPARα activation. Additionally, the study attempts to elucidate whether the transcriptomic response mediated by HFPO-DA is similar in the presence or absence of PPARα, to further understand its mechanism of action.

Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and PPARα knockout mouse hepatocytes

Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in mouse, rat, and pooled human hepatocytes

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.

A Comparative Study of Mouse Hepatic and Intestinal Gene Expression Profiles under PPAR<i>α</i>Knockout by Gene Set Enrichment Analysis

A Meta-Analysis Study of Gene Expression Datasets in Mouse Liver under PPARα Knockout.

A comparative study of mouse hepatic and intestinal gene expression profiles under PPAR knockout by gene set enrichment analysis

Transcriptome and Metabolome analysis reveal HFPO-TA induced disorders of hepatic glucose and lipid metabolism in rat by interfering with PPAR signaling pathway

Hepatic Transcriptome Comparative in Silico Analysis Reveals Similar Pathways and Targets Altered by Legacy and Alternative Per- and Polyfluoroalkyl Substances in Mice

Hepatotoxic Effects of Hexafluoropropylene Oxide Trimer Acid (HFPO-TA), A Novel Perfluorooctanoic Acid (PFOA) Alternative, on Mice

Transcriptome Analysis of 3D Primary Mouse Liver Spheroids Shows That Long-Term Exposure to Hexafluoropropylene Oxide Trimer Acid Disrupts Hepatic Bile Acid Metabolism.

Increased hepatic oxidative metabolism distinguishes the action of Peroxisome proliferator-activated receptor delta from Peroxisome proliferator-activated receptor gamma in the ob/ob mouse

Persistent metabolic toxicities following developmental exposure to hexafluoropropylene oxide trimer acid (HFPO-TA): Roles of peroxisome proliferator activated receptor gamma

Evaluating the mode of action of perfluorooctanoic acid-induced liver tumors in male Sprague-Dawley rats using a toxicogenomic approach

Hepatotoxicity of Perfluorooctanoic Acid and Two Emerging Alternatives Based on a 3D Spheroid Model.

Transcriptomic re-analyses of human hepatocyte spheroids treated with PFAS reveals chain length and dose-dependent modes of action

RNA-sequencing analysis reveals the hepatotoxic mechanism of perfluoroalkyl alternatives, HFPO2 and HFPO4, following exposure in mice.

Modulation Of Ammonium Perfluorooctanoate-Induced Hepatic Damage By Genetically Different Ppar Alpha In Mice

Species Differences between Mouse and Human PPARα in Modulating the Hepatocarcinogenic Effects of Perinatal Exposure to a High-Affinity Human PPARα Agonist in Mice

The Pharmacodynamic And Differential Gene Expression Analysis Of Ppar Alpha/Delta Agonist Gft505 In Cdahfd-Induced Nash Model

Activation of Peroxisome Proliferator-Activated Receptor Α Ameliorates Perfluorododecanoic Acid-Induced Production of Reactive Oxygen Species in Rat Liver